36氪获悉，质肽生物于近日完成近2亿元人民币B+轮融资。领投方为爱美客、中美绿色基金，其他投资方包括嘉远资本、成都科创投、晋成基金等，老股东蓝驰创投持续加码。易凯资本任独家财务顾问。

The CPG industry has been getting involved in GLP-1 popularity recently by prioritizing macros, mainly protein, in a wide range of products. But now a more targeted option opens itself up at the ...

Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...

在肝病和糖尿病领域，中国生物制药布局已久。像2005 年上市的天晴甘美就是公司目前销量第二的肝病药物，也是国家 1 类新药；另外，集团开发的治疗糖尿病药物“西格列汀二甲双胍缓释片”（商品名：品多）已获批，是国内仿制药首家获批上市。

A new study hints that pregnant people who have previously taken drugs like Ozempic may face a higher risk of certain poor pregnancy outcomes. But more studies are needed to understand the finding.

The UC Davis Innovation Institute for Food and Health recently hosted scientists, physicians and industry experts to discuss how drugs based on GLP-1 are transforming treatment for obesity, diabetes ...

After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms have begun turning to a different, less effective medication that has been on ...

1月8日，礼来公布了IIIb期TOGETHER-PsA研究的积极结果。该研究评估了依奇珠单抗联合替尔泊肽治疗活动性银屑病关节炎（PsA）合并肥胖或超重（至少伴有一种体重相关合并症）成年患者的疗效与安全性。结果显示，联合治疗在36周时不仅显著提高同时达 ...

生物制药行业的增长逻辑正在发生深刻变化。GLP-1药物的市场渗透从糖尿病、肥胖症向心血管及神经系统领域外溢；人工智能在药物研发与临床实验设计中的应用进入收获期；加之DTP（直面患者）模式对分销渠道的重塑，行业整体盈利质量和创新转化效率正得到显著提升。